BinaryTuners Co.
'BinaryTuners Co., Ltd.' refers to scientists who develop personalized solutions that assist in the diagnosis, prognosis, and prevention of various modern diseases by analyzing binary data represented by 0s and 1s.
Founded as a bioinformatics company by Professor Lee's lab from the Department of Bio-Convergence Engineering at Dankook University, the company aims to develop traditional medicine-based diagnostic solutions using genomic data.
Competencies
: With experience utilizing various forms of healthcare big data, including genomic data, the company identifies genome-based biomarkers applicable to the diagnosis, prognosis, and treatment of clinical needs related to various modern intractable diseases, such as cancer, autoimmune diseases, and metabolic disorders.
Top-tier expertise in genomic analysis
Based on over 10 years of experience in analyzing various genomic data, the company holds a technological advantage in its analytical capabilities.
Formation of a domestic and international expert network
The company holds a strategic advantage in technological networks, engaging in collaborative genomic analysis research with institutions such as Harvard in the U.S. and major traditional medicine research institutes in Korea.
Integration of traditional medicine and genomic analysis expertise
Understanding the characteristics of genomic data, the company provides a scientific diagnostic service platform based on traditional medicine knowledge.
Ongoing collaborative research with various domestic government research institutes and universities
- Research on the safety of herbal medicine using big data from the Health Insurance Review and Assessment Service
- Establishment of a collaborative care system and evidence-based management of post-surgical cancer sequelae
- Development of a heat-cold pattern differentiation prediction model based on polygenic risk scores
- Discovery of colorectal cancer diagnostic markers based on gut microbiome
- Discovery of new indications for natural product-based anticancer drugs and other diseases
- Discovery of functional materials based on skin microbiota